91470-28-9Relevant articles and documents
Macrocyclic MCL-1 inhibitors and methods of use
-
Paragraph 0916, (2019/02/28)
The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
Heteroalicyclic carboxamidines as inhibitors of inducible nitric oxide synthase; The identification of (2R)-2-pyrrolidinecarboxamidine as a potent and selective haem-co-ordinating inhibitor
Young, Robert J.,Alderton, Wendy,Angell, Anthony D.R.,Beswick, Paul J.,Brown, David,Chambers, C. Lynn,Crowe, Miriam C.,Dawson, John,Hamlett, Christopher C.F.,Hodgson, Simon T.,Kleanthous, Savvas,Knowles, Richard G.,Russell, Linda J.,Stocker, Richard,Woolven, James M.
scheme or table, p. 3037 - 3040 (2011/06/26)
Heteroalicyclic carboxamidines were synthesised and evaluated as inhibitors of nitric oxide synthases. (2R)-2-Pyrrolidinecarboxamidine, in particular, was shown to be a highly potent in vitro (IC50 = 0.12 μM) and selective iNOS inhibitor (>100-fold vs both eNOS and nNOS), with probable binding to the key anchoring glutamate residue and co-ordination to the haem iron.
ALPHA SUBSTITUTED CARBOXYLIC ACID AS PPAR MODULATORS
-
Page 136-137, (2010/02/09)
Alpha substituted carboxylic acids of formula (I): wherein R' and R2 are as defined in the specification and R3 is A) formula (II); B) formula (III); C) formula (IV); and D) formula (V); wherein Y, Art, Are, AP, R4, R5, R6, R7, R6, R9, R9a, R10, R", R12, R17, ring A, and p are as defined in the specification; pharmaceutical compositions containing effective amounts of said compounds or their salts are useful for treating PPAR, specifically PPAR α/y related disorders, such as diabetes, dyslipidemia, obesity and inflammatory disorders.